Rein Therapeutics, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Rein Therapeutics announced preliminary blinded interim data from its Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis: 33% of 24 evaluable patients (8 patients) showed FVC improvement at Week 12; 46% (11 patients) experienced FVC decline ≤5.7%; no serious adverse events attributed to treatment; 92% of enrolled participants remained on study. Trial is 75% enrolled (90 of ~120 patients) and on track to report topline data in 2027. Cash position of $36.5M is expected to fund operations into Q1 2028.
Why this rating
Early-stage biotech with single lead program; encouraging interim safety/lung function trends support Phase 2 progression. Runway to data readout de-risks near-term. Data is blinded, pooled, and not comparative—modest predictive power. Meaningful for company trajectory but not transformational yet.
Tradability signal
NO TRADE
No trade: price $0.30 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.56 ▲ 54.68% | at our read · unknown $0.36 | +10 min · unknown $0.30 ▼ 16.81% | +30 min · unknown $0.40 ▲ 10.98% | +1 hr · unknown $0.43 ▲ 21.13% | +4 hrs · unknown $0.41 ▲ 14.27% |
The stock had already moved -35.35% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.